Patents by Inventor Mickael JEAN

Mickael JEAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and pharmaceutical compositions for reducing CD95-mediated cell motility
    Patent number: 11905253
    Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: February 20, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE RENNES 1, CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, INSTITUT BERGONIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE BORDEAUX
    Inventors: Pierre Vacher, Patrick Legembre, Mickael Jean, Patrick Blanco, Pierre Van De Weghe
  • SYSTEMS, DEVICES, AND METHODS FOR TRANSCUTANEOUS ELECTRICAL STIMULATION
    Publication number: 20240024661
    Abstract: Described here are systems, devices, and methods useful for treating a neurological disorder of a patient. A system for applying transcutaneous electrical stimulation to a patient may comprise an electrode configured to be coupled to a forehead of the patient. The electrode may comprise a substrate, a first conductor, a second conductor, and an insulator each disposed on the substrate. The insulator may be positioned laterally between the first and second conductor. The first and second conductors may be configured to stimulate a trigeminal nerve of the patient. An electrode identifier may be disposed on the substrate and across the first and second conductors. A housing may be configured to releasably couple to the electrode. The housing may comprise a signal generator configured to generate a set of pulses for the electrode.
    Type: Application
    Filed: May 19, 2023
    Publication date: January 25, 2024
    Inventors: Jennifer TRAINOR-MCDERMOTT, Mickaël JEAN, Michael JOHNSON, Jeroen WILMS, Michaël BURM, Robrecht Van VELTHOVEN, Laurent HOUTSAEGER
  • COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95-MEDIATED CELL MOTILITY
    Publication number: 20210238143
    Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 5, 2021
    Inventors: Pierre VACHER, Patrick LEGEMBRE, Mickael JEAN, Patrick BLANCO, Pierre VAN DE WEGHE
  • PI3K/AKT/mTOR inhibitors and pharmaceutical uses thereof
    Patent number: 9656984
    Abstract: The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: May 23, 2017
    Assignees: UNIVERSITE DE RENNES 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mickael Jean, Amélie Fouque, Patrick Legembre, Pierre Van De Weghe
  • NEW PI3K/AKT/MTOR INHIBITORS AND PHARMACEUTICAL USES THEREOF
    Publication number: 20160244424
    Abstract: The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.
    Type: Application
    Filed: September 24, 2014
    Publication date: August 25, 2016
    Applicants: UNIVERSITE DE RENNES 1, Centre national de la recherche scientifique, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mickael JEAN, Amélie FOUQUE, Patrick LEGEMBRE, Pierre VAN DE WEGHE